[HTML] cell.comFull View

[HTML][HTML] CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer

JH Hwang, JH Seo, ML Beshiri, S Wankowicz, D Liu… - Cell Reports, 2019 - cell.com
Summary Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment
of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients …
被引用次数：55 相关文章 所有 10 个版本
[PDF] elifesciences.org

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies

JH Hwang, R Arafeh, JH Seo, SC Baca, M Ludwig… - Elife, 2022 - elifesciences.org
Metastatic castration-resistant prostate cancers (mCRPCs) are treated with therapies that
antagonize the androgen receptor (AR). Nearly all patients develop resistance to AR …
被引用次数：11 相关文章 所有 10 个版本
[HTML] nih.gov

Phase II multicenter study of enzalutamide in metastatic castration-resistant prostate cancer to identify mechanisms driving resistance

RR McKay, L Kwak, JP Crowdis, JM Sperger… - Clinical Cancer …, 2021 - AACR
Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that has
improved overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC) …
被引用次数：24 相关文章 所有 5 个版本
[HTML] nih.gov

Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro

SE Kohrt, WN Awadallah, RA Phillips III, TC Case… - Molecular cancer …, 2021 - AACR
Castration-resistant prostate cancer can be treated with the antiandrogen enzalutamide, but
responses and duration of response are variable. To identify genes that support …
被引用次数：20 相关文章 所有 7 个版本
[HTML] nih.gov

A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer

Y Rodríguez, K Unno, MI Truica, ZR Chalmers, YA Yoo… - Cancer research, 2022 - AACR
Androgen receptor (AR) pathway inhibitors are the mainstay treatment for advanced prostate
cancer, but resistance to therapy is common. Here, we used a CRISPR activation screen in …
被引用次数：13 相关文章 所有 6 个版本
[PDF] nature.com

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated …

SAL Palit, J van Dorp, D Vis, C Lieftink, S Linder… - Scientific reports, 2021 - nature.com
Resistance to drugs targeting the androgen receptor (AR) signaling axis remains an
important challenge in the treatment of prostate cancer patients. Activation of alternative …
被引用次数：14 相关文章 所有 8 个版本
[PDF] aacrjournals.org

Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells

W Pan, Z Zhang, H Kimball, F Qu, K Berlind… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: Abiraterone acetate (AA), an inhibitor of cytochrome P450 17alpha-
hydroxylase/17, 20 lyase, is an FDA-approved drug for advanced prostate cancer. However …
被引用次数：25 相关文章 所有 4 个版本
[PDF] nature.com

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity

TC Westbrook, X Guan, E Rodansky, D Flores… - Nature …, 2022 - nature.com
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …
被引用次数：23 相关文章 所有 12 个版本
[PDF] nature.com

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress …

FJ Chou, CY Lin, H Tian, WY Lin, B You, J Lu… - Cell death & …, 2020 - nature.com
The FDA-approved anti-androgen Enzalutamide (Enz) has been used successfully as the
last line therapy to extend castration-resistant prostate cancer (CRPC) patients' survival by …
被引用次数：14 相关文章 所有 6 个版本
[HTML] nih.gov

[HTML][HTML] Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

S Kregel, JL Chen, W Tom, V Krishnan, J Kach… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with
proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority …
被引用次数：115 相关文章 所有 10 个版本